Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164083 | 0.85 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL20512001 | 0.84 | CES2 (0.39) | CES2CES1DPP4DPP7 | |
| SCHEMBL20164093 | 0.83 | CES2 (0.40) | CES2CES1 | |
| SCHEMBL20511998 | 0.82 | CA1 (0.30) | — | |
| SCHEMBL20164098 | 0.82 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL18249655 | 0.81 | CES2 (0.41) | CES2CES1TRPM8DPP4FAP | |
| SCHEMBL20164104 | 0.80 | CES2 (0.38) | CES2CES1 | |
| SCHEMBL18249648 | 0.79 | CES2 (0.36) | CES2CES1TRPM8 | |
| SCHEMBL18249594 | 0.77 | DPP4 (0.42) | CES2CES1DPP4 | |
| Oxalic Acid SCHEMBL18249573 | 0.76 | CES2 (0.37) | CES2CES1TRPM8DPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES (SE) | 2018-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A1 | CES2 161/4885CES1 2089/4885TRPM8 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.